Denmark's IO Vaccine Biotech Attracts Investor Interest

IO Biotech's Oversubscribed €127m Series B

Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.  

Business team present.
• Source: Shutterstock

An immuno-oncology start-up biotech with two candidate anticancer immune-modulating vaccines already in clinical studies, IO Biotech ApS, has attracted new and existing investors to an oversubscribed €127m series B financing, one of the largest in Europe over past months. 

Copenhagen, Denmark-based IO Biotech was spun out of the Centre for Cancer Immune Therapy (CCIT), University of Copenhagen Herlev Hospital...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer